Multiple sclerosis is linked to MAPKERK overactivity in microglia
George J A Ten Bosch1, Jolande Bolk2, Bert A 't Hart3,4
1Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. gjatenbosch2019@outlook.com.
Abstract:
Reassessment of published observations in patients with multiple sclerosis (MS) suggests a microglial malfunction due to inappropriate (over)activity of the mitogen-activated protein kinase pathway ERK (MAPKERK). These observations regard biochemistry as well as epigenetics, and all indicate involvement of this pathway. Recent preclinical research on neurodegeneration already pointed towards a role of MAPK pathways, in particular MAPKERK. This is important as microglia with overactive MAPK have been identified to disturb local oligodendrocytes which can lead to locoregional demyelination, hallmark of MS. This constitutes a new concept on pathophysiology of MS, besides the prevailing view, i.e., autoimmunity. Acknowledged risk factors for MS, such as EBV infection, hypovitaminosis D, and smoking, all downregulate MAPKERK negative feedback phosphatases that normally regulate MAPKERK activity. Consequently, these factors may contribute to inappropriate MAPKERK overactivity, and thereby to neurodegeneration. Also, MAPKERK overactivity in microglia, as a factor in the pathophysiology of MS, could explain ongoing neurodegeneration in MS patients despite optimized immunosuppressive or immunomodulatory treatment. Currently, for these patients with progressive disease, no effective treatment exists. In such refractory MS, targeting the cause of overactive MAPKERK in microglia merits further investigation as this phenomenon may imply a novel treatment approach.
Insights
Multiple sclerosis (MS) may stem from overactive mitogen-activated protein kinase ERK (MAPKERK) in microglia, disrupting myelin. This pathway dysfunction, linked to MS risk factors, offers a new therapeutic target for neurodegeneration.
Area of Science:
- Neuroimmunology
- Neurodegeneration
- Molecular Biology
Background:
- Multiple sclerosis (MS) pathophysiology is primarily viewed as autoimmune.
- Microglial dysfunction has been implicated in neurodegenerative processes.
- Mitogen-activated protein kinase (MAPK) pathways, particularly MAPKERK, are increasingly recognized in neurodegeneration.
Purpose of the Study:
- To reassess published observations in MS patients to propose a new pathophysiological concept.
- To investigate the role of microglial mitogen-activated protein kinase ERK (MAPKERK) overactivity in MS.
- To explore potential novel therapeutic targets for refractory MS.
Main Methods:
- Reanalysis of existing biochemical and epigenetic data from MS patients.
- Review of preclinical research on MAPK pathways in neurodegeneration.
- Correlation of known MS risk factors with MAPKERK pathway regulation.
Main Results:
- Published data suggest microglial malfunction due to inappropriate MAPKERK overactivity in MS.
- MAPKERK overactivity in microglia can disturb oligodendrocytes, leading to demyelination.
- MS risk factors (EBV, hypovitaminosis D, smoking) downregulate MAPKERK negative feedback, potentially causing pathway overactivity.
Conclusions:
- Microglial MAPKERK overactivity presents a novel pathophysiological concept for MS, distinct from autoimmunity.
- This pathway dysfunction may explain persistent neurodegeneration in MS patients undergoing treatment.
- Targeting MAPKERK overactivity in microglia could represent a new therapeutic strategy for progressive and refractory MS.
More Related Videos
Related Concept Videos
MAPK Signaling Cascades
Microtubule Associated Proteins (MAPs)
Microtubule Instability
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...


